BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGCD290: Phase I data

In a double-blind, placebo-controlled, Canadian Phase I trial (Study 290-003) in 32 healthy volunteers, once-daily 100-540 mg oral MGCD290 for 14 days produced no...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >